Literature DB >> 17892157

Marker vaccines and the impact of their use on diagnosis and prophylactic measures.

P Vannie1, I Capua, M F Le Potier, D K J Mackay, B Muylkens, S Parida, D J Paton, E Thiry.   

Abstract

Molecular biology and technical advances in DNA recombination have ushered in a new era in vaccinology. This article examines the recent development of specific marker vaccines and examines the impact of their use on the diagnosis and prevention of major infectious diseases. Gene-deleted vaccines, DIVA strategies (differentiating infected from vaccinated animals) and similar methods have been successfully applied in the control and eradication of Aujeszky's disease, infectious bovine rhinotracheitis, classical swine fever, foot and mouth disease and, recently, avian influenza. The efficacy and performance of existing marker vaccines and their companion diagnostic tools (which should be assesed by an independent body) are discussed, as are the ways in which these tools are deployed by competent authorities. The limits and the advantages of the use of marker vaccines are carefully analysed in the light of practical experiences. Although these vaccines can limit the speed and the extent of virus dissemination and thus reduce the number of animals slaughtered, marker vaccines are no substitute for sanitary measures. Early detection and warning systems and the quick implementation of sanitary measures, including stamping out, remain key issues in the control of highly contagious diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892157

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  8 in total

1.  Genetic characterization of avian influenza viruses isolated in Israel during 2000-2006.

Authors:  Natalia Golender; Alexander Panshin; Caroline Banet-Noach; Sagit Nagar; Shimon Pokamunski; Michael Pirak; Yevgeny Tendler; Irit Davidson; Maricarmen García; Shimon Perk
Journal:  Virus Genes       Date:  2008-08-20       Impact factor: 2.332

Review 2.  Options for control of foot-and-mouth disease: knowledge, capability and policy.

Authors:  David J Paton; Keith J Sumption; Bryan Charleston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-09-27       Impact factor: 6.237

3.  Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge.

Authors:  Franziska Kraatz; Kerstin Wernike; Silke Hechinger; Patricia König; Harald Granzow; Ilona Reimann; Martin Beer
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

Review 4.  Development of vaccines against Crimean-Congo haemorrhagic fever virus.

Authors:  Stuart D Dowall; Miles W Carroll; Roger Hewson
Journal:  Vaccine       Date:  2017-07-04       Impact factor: 3.641

Review 5.  A decade of research into classical swine fever marker vaccine CP7_E2alf (Suvaxyn® CSF Marker): a review of vaccine properties.

Authors:  Sandra Blome; Kerstin Wernike; Ilona Reimann; Patricia König; Claudia Moß; Martin Beer
Journal:  Vet Res       Date:  2017-09-15       Impact factor: 3.683

6.  The LORF5 Gene Is Non-essential for Replication but Important for Duck Plague Virus Cell-to-Cell Spread Efficiently in Host Cells.

Authors:  Bingjie Shen; Yunjiao Li; Anchun Cheng; Mingshu Wang; Ying Wu; Qiao Yang; Renyong Jia; Bin Tian; Xumin Ou; Sai Mao; Di Sun; Shaqiu Zhang; Dekang Zhu; Shun Chen; Mafeng Liu; Xin-Xin Zhao; Juan Huang; Qun Gao; Yunya Liu; Yanling Yu; Ling Zhang; Leichang Pan
Journal:  Front Microbiol       Date:  2021-12-02       Impact factor: 5.640

Review 7.  Review: Capripoxvirus Diseases: Current Status and Opportunities for Control.

Authors:  E S M Tuppurainen; E H Venter; J L Shisler; G Gari; G A Mekonnen; N Juleff; N A Lyons; K De Clercq; C Upton; T R Bowden; S Babiuk; L A Babiuk
Journal:  Transbound Emerg Dis       Date:  2015-11-13       Impact factor: 5.005

Review 8.  Accidental introduction of viruses into companion animals by commercial vaccines.

Authors:  James F Evermann
Journal:  Vet Clin North Am Small Anim Pract       Date:  2008-07       Impact factor: 2.093

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.